Supplemental Material for: Dupilumab-responsive Grover disease with concomitant eczematous dermatitis: a case report and review of 27 cases

Emerging evidence suggests that type 2 (Th2) inflammation may contribute to GD pathogenesis. Accordingly, dupilumab has emerged as a potential therapy for recalcitrant GD.

The clinical features that correlate with response remain incompletely defined; however, atopic history has been proposed as one potential marker.</p><p dir="ltr">Case Presentation: A 68-year-old man with biopsy-confirmed GD and concomitant late-onset eczematous dermatitis, but no prior atopic history, presented with severe truncal pruritus refractory to topical and antihistamine therapies. After starting dupilumab, pruritus improved within one day, and his GD lesions had fully resolved by three months.</p><p dir="ltr">Conclusion: Our case expands the spectrum of patients with GD who may benefit from dupilumab, lends further support for the role of Th2 cytokines in GD pathogenesis, and highlights eczematous inflammation as a feature warranting further study.